GlassScriptPhysician profile
Dorothy Marie Dewitt
NPI 1306477310
$8,923.14
in general payments reported to CMS, 2019-2025
56 companies · $73.14 in 2025
The $73.14 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,876 · 2022: $1,905 · 2023: $2,340 · 2024: $2,728 · 2025: $73.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,064 · Education: $77.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,063.77 |
| Education | $77.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $868.94 | 2021-2024 | Lumakras, Imdelltra (Amg 757), Kyprolis |
| Astrazeneca Pharmaceuticals LP | $798.22 | 2021-2024 | Calquence, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $672.91 | 2021-2025 | |
| Janssen Biotech, INC. | $512.04 | 2021-2024 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $445.16 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $442.94 | 2022-2024 | Opdivo, Augtyro |
| Genentech USA, INC. | $378.25 | 2021-2024 | Tecentriq, Perjeta, Phesgo |
| Astellas Pharma US INC | $324.34 | 2021-2024 | Padcev, Xtandi, Xospata |
| Merck Sharp & Dohme LLC | $298.13 | 2021-2024 | Keytruda, Welireg |
| Incyte Corporation | $237.90 | 2021-2023 | Jakafi |
| Daiichi Sankyo INC. | $237.63 | 2021-2024 | Enhertu, Vanflyta |
| Seagen INC. | $225.45 | 2021-2023 | Padcev |
| Eisai INC. | $218.47 | 2021-2024 | |
| Abbvie INC. | $210.15 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $208.40 | 2021-2024 | Rezlidhia, Tavalisse |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.